首页> 美国卫生研究院文献>Memrias do Instituto Oswaldo Cruz >A serological parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention
【2h】

A serological parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention

机译:介入治疗前后三年未治疗的恰加斯病患者和苯并硝唑治疗患者的血清学寄生虫学和临床评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The etiological treatment of Chagas disease is recommended for all patients with acute or recent chronic infection, but controversies remain regarding the benefit of chemotherapy and interpretations of the parasitological cure after etiological treatment. This study compares the laboratory and clinical evaluations of Chagas disease patients who were diagnosed 13 years earlier. Fifty-eight Chagas disease patients (29 treated with benznidazole and 29 untreated) were matched at the time of treatment based on several variables. Conventional serology revealed the absence of seroconversion in all patients. However, lower serological titres were verified in the treated group, primarily among patients who had the indeterminate form of the disease. Haemoculture performed 13 years after the intervention was positive for 6.9% and 27.6% of the treated and untreated patients, respectively. Polymerase chain reaction tests were positive for 44.8% and 13.8% of the treated and untreated patients, respectively. Patients who presented with the indeterminate form of the disease at the beginning of the study exhibited less clinical progression (17.4%) compared with the untreated group (56.5%). Therefore, this global analysis revealed that etiological treatment with benznidazole may benefit patients with respect to the clinical progression of Chagas disease and the prognosis, particularly when administered to patients with the indeterminate form of the disease.
机译:建议对所有患有急性或近期慢性感染的患者进行查加斯病的病因学治疗,但是关于化学疗法的益处以及病因学治疗后对寄生虫病治愈的解释仍存在争议。这项研究比较了13年前被诊断出的恰加斯病患者的实验室和临床评估。根据一些变量,在治疗时对58例恰加斯病患者(29例用苯硝唑治疗,29例未治疗)进行了匹配。常规血清学检查显示所有患者均无血清转换。但是,治疗组的血清滴度较低,主要是在该病类型不确定的患者中。干预13年后进行的血液培养阳性,分别占治疗和未治疗患者的6.9%和27.6%。聚合酶链反应测试分别对接受治疗和未经治疗的患者呈阳性,分别为44.8%和13.8%。与未治疗组(56.5%)相比,在研究开始时表现为不确定形式疾病的患者表现出较少的临床进展(17.4%)。因此,这一整体分析表明,用苯硝唑进行病原学治疗可能会给患者带来恰加斯病的临床进展和预后方面的益处,特别是对不确定形式的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号